Milurit (Allopurinol)

Allopurinol is a competitive inhibitor of the enzyme xanthine oxidase. By blocking this enzyme, it reduces the conversion of hypoxanthine and xanthine into uric acid, thereby decreasing the amount of uric acid produced in the body and limiting crystal formation in joints and kidneys.

The appropriate dose of Milurit is determined by the prescribing healthcare professional based on the individual’s condition, renal function, and response to therapy. Dosage may be started low and titrated upward, but exact amounts should only be set by a qualified prescriber.

Allopurinol’s pregnancy category is not definitively established, and safety data are limited. It should only be used during pregnancy or lactation when the potential benefit outweighs any possible risk to the fetus or infant, and under close medical supervision.

To request Milurit, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to allopurinol is febuxostat, another xanthine oxidase inhibitor. Both lower uric acid, but febuxostat may be preferred in patients with moderate renal impairment because it is less dependent on renal clearance. However, allopurinol remains the first‑line choice for most patients due to its long‑standing safety profile and lower cost.

Milurit tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging, protect from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability throughout its shelf life.

Milurit is taken orally, usually with a full glass of water. It can be taken with or without food, but consistent administration with meals may reduce gastrointestinal discomfort. Patients should follow the prescriber’s instructions regarding timing and any dose‑adjustments.

The most severe adverse events include hypersensitivity reactions such as Stevens‑Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS). Agranulocytosis, severe hepatitis, and acute renal failure are also rare but critical complications that require immediate medical attention.

Milurit should be avoided in patients with a known hypersensitivity to allopurinol or any component of the formulation. Caution is also advised for individuals with severe renal or hepatic impairment, and it is contraindicated in patients receiving concurrent azathioprine or mercaptopurine without dose adjustment.